Boron neutron capture therapy for advanced salivary gland carcinoma in head and neck
Boron neutron capture therapy for advanced salivary gland carcinoma in head and neck
复制标题
DOI：
10.1007/s10147-013-0580-3
复制
发表时间：
2014-06-01
影响因子：
3.3
通讯作者：
Harada, Tamotu
中科院分区：
文献类型：
--
作者：
Aihara, Teruhito;Morita, Norimasa;Harada, Tamotu
硼中子俘获疗法（BNCT）是已知对肿瘤细胞具有选择性致死作用的放射治疗之一。本研究总结了2003年10月至2007年9月期间，经川崎医科大学和京都大学医学伦理委员会批准，2例复发性和3例新诊断的T4晚期涎腺癌患者接受BNCT治疗的肿瘤反应和急性及晚期不良反应。在日本4号研究堆中，使用超热束进行了单次BNCT。所有患者在治疗6个月内获得了完全缓解。完全缓解的中位持续时间为24.0个月;中位总生存时间为32.0个月。5例患者中有3例仍然存活，另外2例死于远处转移性疾病。1例患者在BNCT后进行腮腺开放活检，未发现残留的活癌细胞，正常腺体系统无严重损伤。虽然所有患者都出现轻度脱发、口干和疲劳，但没有出现3级或更高的严重不良反应。我们的初步结果表明，BNCT是一种潜在的治疗涎腺癌患者的治疗方法。该治疗不会引起任何严重的不良反应，并且无论原发性肿瘤先前是否接受过治疗，都可以使用。
Boron neutron capture therapy (BNCT) is among the radiation treatments known to have a selective lethal effect on tumor cells. This study summarizes the tumor responses and the acute and late adverse effects of BNCT in the treatment of patients with both recurrent and newly diagnosed T4 salivary gland carcinoma.Two patients with recurrent cancer and 3 with newly diagnosed T4 advanced malignancy were registered between October 2003 and September 2007, with the approval of the medical ethics committees of Kawasaki Medical School and Kyoto University. BNCT was performed, in a single fraction using an epithermal beam, at Japan Research Reactor 4.All patients achieved a complete response within 6 months of treatment. The median duration of the complete response was 24.0 months; the median overall survival time was 32.0 months. Three of the 5 patients are still alive; the other 2 died of distant metastatic disease. Open biopsy of the parotid gland after BNCT was performed in 1 patient and revealed no residual viable cancer cells and no serious damage to the normal glandular system. Although mild alopecia, xerostomia, and fatigue occurred in all patients, there were no severe adverse effects of grade 3 or greater.Our preliminary results demonstrate that BNCT is a potential curative therapy for patients with salivary gland carcinoma. The treatment does not cause any serious adverse effects, and may be used regardless of whether the primary tumor has been previously treated.